Cargando…
Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2
Following the emergence of SARS-CoV-2, the search for an effective and rapidly available treatment was initiated worldwide based on repurposing of available drugs. Previous reports described the antiviral activity of certain tyrosine kinase inhibitors (TKIs) targeting the Abelson kinase 2 against pa...
Autores principales: | Touret, Franck, Driouich, Jean-Sélim, Cochin, Maxime, Petit, Paul Rémi, Gilles, Magali, Barthélémy, Karine, Moureau, Grégory, Mahon, Francois-Xavier, Malvy, Denis, Solas, Caroline, de Lamballerie, Xavier, Nougairède, Antoine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274277/ https://www.ncbi.nlm.nih.gov/pubmed/34265358 http://dx.doi.org/10.1016/j.antiviral.2021.105137 |
Ejemplares similares
-
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2021) -
Hydroxychloroquine and azithromycin used alone or combined are not effective against SARS-CoV-2 ex vivo and in a hamster model
por: Cochin, Maxime, et al.
Publicado: (2022) -
Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2
por: Driouich, Jean-Sélim, et al.
Publicado: (2022) -
Replicative Fitness of a SARS-CoV-2 20I/501Y.V1 Variant from Lineage B.1.1.7 in Human Reconstituted Bronchial Epithelium
por: Touret, Franck, et al.
Publicado: (2021) -
The SARS-CoV-2 Alpha variant exhibits comparable fitness to the D614G strain in a Syrian hamster model
por: Cochin, Maxime, et al.
Publicado: (2022)